Effects of repeated nicotine pre-treatment on mesoprefrontal dopaminergic and behavioral responses to acute footshock stress

Brain Research

Volumn 801, Issue 1-2, 1998, Pages 36-49

  George, Tony P ^a   Verrico, Christopher D ^a   Roth, Robert H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Nicotine; Prefrontal cortex; Rat brain; Schizophrenia; Stress

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; MECAMYLAMINE; NICOTINE; NICOTINIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; ELECTRIC SHOCK; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMOBILIZATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SHOCK; STRESS;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; ELECTROSHOCK; FOOT; IMMOBILIZATION; INJECTIONS; MALE; MECAMYLAMINE; NICOTINE; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; STRESS;

EID: 0032504716     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00537-X     Document Type: Article

References (56)

1. Aceto M.D., Scates S.M., Ji Z., Bowman E.R. Nicotine's opioid and anti-opioid interactions: proposed role in smoking behavior. Eur. J. Pharmacol. 248:1993;333-335.
2. Arnsten A.F.T., Goldman-Rakic P.S. Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. Arch. Gen. Psychiatry. 55:1998;362-368.
3. Benwell M.E.M., Balfour D.J.K. The effects of chronic nicotine administration on the response and adaptation to stress. Psychopharmacology. 76:1982;160-162.
4. Benwell M.E.M., Balfour D.J.K. Regional variation in the effects of nicotine on catecholamine overflow in rat brain. Eur. J. Pharmacol. 325:1992;13-20.
5. Breslau N. Psychiatric comorbidity of smoking and nicotine dependence. Behav. Genet. 25:1995;95-101.
6. Brioni J.D., O'Neill A.B., Kim D.J.B., Decker M.W. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur. J. Pharmacol. 238:1993;1-8.
7. Carr L.A., Rowell P.P., Pierce W.M. Jr. Effects of subchronic nicotine administration on central dopaminergic mechanisms in the rat. Neurochem. Res. 14:1989;511-515.
8. Christensen M.-K., Smith D.F. Antinociceptive effects of the stereoisomers of nicotine given intrathecally in spinal rats. J. Neural Transm. (Gen Sect.). 80:1990;189-194.
9. Clarke P.B.S., Pert A. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic projections. Brain Res. 348:1985;355-358.
10. Clarke P.B.S., Fu D.S., Jakubovic A., Fibiger H.C. Evidence that mesolimbic dopamine activation underlies the locomotor stimulant action of nicotine in rats. J. Pharmacol. Exp. Ther. 246:1988;701-708.
11. Collins A.C., Romm E., Wehner J.M. Dissociation of the apparent relationship between nicotine tolerance and up-regulation of nicotinic receptors. Brain Res. Bull. 25:1990;373-379.
12. Conti L.H., Naeiver C.R., Ferkany J.W., Abreau M.E. Footshock induced freezing behavior in rats as a model for assessing anxiolytics. Psychopharmacology. 102:1990;492-497.
13. Corrigall W.A., Franklin K.B.J., Coen K.M., Clarke P.B.S. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology. 107:1992;285-289.
14. Damsma G., Day J., Fibiger H.C. Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 168:1989;363-368.
15. Davis M., Astrachan D.I. Conditioned fear and startle magnitude: effects of different footshock or barshock intensities used in training. J. Exp. Psychol. 4:1978;95-103.
16. Elsworth J.D., Brittan M.S., Taylor J.R., Sladek J.R., Al-Tikriti M.S., Zea-Ponce Y., Innis R.B., Redmond D.E. Jr., Roth R.H. Restoration of dopamine transporter density in the striatum of fetal ventral mesencephalon-grafted, but not sham-grafted, MPTP-treated parkinsonian monkeys. Cell Transplant. 5:1996;315-325.
17. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. USA. 94:1997;587-592.
18. Fung Y.K., Schmid M.J., Anderson T.M., Lau Y.-S. Effects of nicotine withdrawal on central dopaminergic systems. Pharmacol. Biochem. Behav. 53:1996;635-640.
19. Gilbert D.G., Estes S.L., Welser R. Does noise stress modulate effects of smoking/nicotine? Mood, vigilance and EEG responses. Psychopharmacology. 129:1997;382-389.
20. Glassman A.H. Cigarette smoking: implications for psychiatric illness. Am. J. Psychiatry. 150:1993;546-553.
21. Goldberg S.R., Henningfield J.E. Reinforcing effects of nicotine in humans and experimental animals responding under intermittent schedules of i.v. drug injection. Pharmacol. Biochem. Behav. 30:1988;227-234.
22. Goldman-Rakic P.S., Selemon L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophrenia Bull. 23:1997;437-458.
23. Hall G.H., Morrison C.F. New evidence for a relationship between tobacco smoking, nicotine dependence and stress. Nature. 243:1973;199-201.
24. J.E. Henningfield, L.M. Schuh, M.E. Jarvik, Pathophysiology of tobacco dependence, in: Psychopharmacology: The 4th Generation of Progress, Raven Press, New York, 1995, pp. 1715-1729.
25. Hildebrand B.E., Nomikos G.G., Panagis G., Hertel P., Schilstrom B., Svensson T.H. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res. 779:1998;214-225.
26. Horger B.A., Roth R.H. The role of mesoprefrontal dopamine neurons in stress. Crit. Rev. Neurobiol. 10:1996;395-418.
27. Imperato A., Mulas A., DiChiara G. Nicotine preferentially stimulates dopamine release in the limbic system in freely moving rats. Eur. J. Pharmacol. 90:1986;468-470.
28. Ikemoto S., Kohl R.R., McBride W.J. GABAA receptor blockade in the anterior ventral tegmental area increases extracellular levels of dopamine in the nucleus accumbens of rats. J. Neurochem. 69:1997;137-143.
29. Jentsch J.D., Tran A., Le D., Youngren K.D., Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology. 17:1997;92-99.
30. Jentsch J.D., Redmond D.E. Jr., Elsworth J.D., Taylor J.R., Youngren K.D., Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 277:1997;953-955.
31. Kalivas P.W., Duffy P. Similar effects of daily cocaine and stress on mesocorticolimbic dopamine neurotransmission in the rat. Biol. Psychiatry. 25:1989;913-928.
32. Knable M.B., Weinberger D.R. R.Do Dopamine, the prefrontal cortex and schizophrenia. J. Psychopharmacol. 11:1997;123-131.
33. Levin E.D. Nicotinic systems and cognitive function. Psychopharmacology. 108:1992;417-431.
34. Levin E.D., Wilson W., Rose J.E., McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology. 15:1996;429-436.
35. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the phenol-folin reagent. J. Biol. Chem. 193:1957;265-275.
36. Morrow B.A., Taylor J.R., Roth R.H. Prior exposure to cocaine diminishes behavioral and biochemical responses to aversive conditioning: reversal by glycine/NMDA antagonist co-treatment. Neuroscience. 69:1995;233-240.
37. Murphy B.L., Arnsten A.F.T., Goldman-Rakic P.S., Roth R.H. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc. Natl. Acad. Sci. USA. 93:1996;1325-1329.
38. Nisell M., Nomikos G.G., Svennson T.H. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol. Toxicol. 76:1995;157-162.
39. Nisell M., Nomikos G.G., Hertel P., Panagis G., Svennson T.H. Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. Synapse. 22:1996;369-381.
40. Nisell M., Marcus M., Nomikos G.G., Svensson T.H. Differential effects of acute and chronic nicotine on dopamine output in the core and shell of the rat nucleus accumbens. J. Neural Transm. 104:1997;1-10.
41. Nuechterlein K.H., Dawson M.E., Ventura J., Gitlin M., Subotnik K.L., Snyder K.S., Mintz J., Bartzokis G. The vulnerability/stress model of schizophrenic relapse: a longitudinal study. Acta Psychiatr. Scand. Suppl. 382:1994;58-64.
42. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, 2nd edn., Academic Press, San Diego, 1986.
43. Picciotto M.R., Zoli M., Rimondini R., Lena C., Marublo L.M., Merlo Pich E., Fuxe K., Changeaux J.-P. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature. 391:1998;173-177.
44. Pidoplichko V.I., DeBias M., Williams J.T., Dani J.A. Nicotine activates and desensitizes midbrain dopamine neurons. Nature. 390:1997;401-404.
45. Pontieri F.E., Tanda G., Orzi F., DiChiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 382:1996;255-257.
46. Pratt J.A., Stolerman I.P., Garcha H.S., Giardini V., Feyerabend C. Discriminative stimulus properties of nicotine: further evidence for mediation at a cholinergic receptor. Psychopharmacology. 81:1983;54-60.
47. Rasmussen K., Czachura J. Nicotine withdrawal leads to increased firing rates of midbrain DA neurons. NeuroReport. 7:1995;329-332.
48. Robinson T.E., Becker J.B., Moore C.J., Castaneda E., Mittleman G. Enduring enhancement in frontal cortex dopamine utilization in an animal model of amphetamine psychosis. Brain Res. 343:1985;374-377.
49. Rosencrans J.A. The psychopharmacological basis of nicotineís differential effects on behavior: individual subject variability in the rat. Behav. Genet. 25:1995;187-196.
50. R.H. Roth, J.D. Elsworth, Biochemical pharmacology of midbrain dopamine neurons, in: F.E. Bloom, D.J. Kupfer (Eds.), Psychopharmacology: The 4th Generation of Progress, Chap. 21, 4th edn., Raven Press, New York, 1995, pp. 227-243.
51. Salin-Pascual R.J., Rosas M., Jimenez-Genchi A., Rivera-Meza B.L., Delgado-Parra V. Antidepressant effect of transdermal nicotine patches in non-smoking patients with major depression. J. Clin. Psychiatry. 57:1996;387-389.
52. Shoaib M., Stolerman I.P., Kumar R.C. Nicotine-induced place preferences following prior nicotine exposure in rats. Psychopharmacology. 113:1994;445-452.
53. Sorg B.A., Kalivas P.W. Effects of cocaine and footshock stress on extracellular dopamine levels in the medial prefrontal cortex. Neuroscience. 53:1993;695-703.
54. Thierry A.M., Tassin J.P., Blanc G., Glowinski J. Selective activation of the mesocortical dopamine system by stress. Nature. 263:1976;242-244.
55. Vezina P., Blanc G., Glowinski J., Tassin J.-P. Nicotine and morphine differentially activate brain dopamine in prefrontocortical and subcortical terminal fields: effects of acute and repeated injections. J. Pharmacol. Exp. Ther. 261:1992;484-490.
56. Ziedonis D.M., George T.P. Schizophrenia and nicotine use: a report on a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophrenia Bull. 23:1997;247-254.